Published in
Taylor and Francis Group, Scandinavian Journal of Gastroenterology, 9(56), p. 1040-1048, 2021
DOI: 10.1080/00365521.2021.1946588
Links
Tools
Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases
Journal article published in 2021 by
Mohamed Attauabi 
,
Camilla Höglund,
Janne Fassov,
Kenneth Bo Pedersen,
Heidi Bansholm Hansen,
Signe Wildt,
Michael Dam Jensen,
Anders Neumann,
Cecilie Lind,
Henrik Albaek Jacobsen,
Ana-Maria Popa,
Jens Kjeldsen,
Natalia Pedersen,
Akbar Molazahi,
Kent Haderslev
and other authors.
,
Camilla Höglund,
Janne Fassov,
Kenneth Bo Pedersen,
Heidi Bansholm Hansen,
Signe Wildt,
Michael Dam Jensen,
Anders Neumann,
Cecilie Lind,
Henrik Albaek Jacobsen,
Ana-Maria Popa,
Jens Kjeldsen,
Natalia Pedersen,
Akbar Molazahi,
Kent Haderslev
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 